

Amyloid PET quantification protocol and imaging charter

Publishable Summary

The Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) Diagnostic and Patient Management Study (DPMS) aim is to determine the utility of A β positron emission tomography (PET) imaging with regards to change in diagnosis, diagnostic confidence, decision trees, and alterations between planned and actual patient management plans.

Successful quantification of amyloid PET imaging is a complex process that requires specialized imaging equipment, processing pipelines and qualified personnel. For the AMYPAD study, detailed criteria were developed for the qualification of imaging sites to ensure the acquisition of data suitable for quantitative analysis and disclosed in a detailed imaging charter

While the main outcome measurement of amyloid load in the DPMS will consist of visual reading measurements, quantitative measurements of amyloid load will also be obtained for secondary endpoints. GE Healthcare will perform the quantification on their premises, with a PET-only analysis suite based on GEHC's CortexID Suite, but which also is specifically customized for AMYPAD in order to derive amyloid load in Centiloid units.

In the end, IXICO will derive the quantitative endpoints from the measurements provided by GEHC and collected from sites.

For more information: info@amypad.org

Acknowledgement: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

